Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 5/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | EYA2 | O00167 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6840742 | 0.98 | NR1D1 (0.34) | NR1D1NR1H3CA12CA1CA7 | |
| SCHEMBL8412077 | 0.96 | NR1D1 (0.34) | NR1D1NR1H3CA12CA1CA7 | |
| SCHEMBL18362362 | 0.96 | NR1D1 (0.33) | NR1D1NR1H3CA12CA1CA7 | |
| SCHEMBL2185399 | 0.93 | TDP1 (0.43) | NR1D1NR1H3CA1EYA2APP | |
| SCHEMBL21548073 | 0.93 | NR1D1 (0.33) | NR1D1NR1H3 | |
| SCHEMBL3661157 | 0.89 | STING1 (0.31) | NR1D1NR1H3 | |
| SCHEMBL6534683 | 0.89 | NR1D1 (0.34) | NR1D1NR1H3CA12CA1CA7 | |
| SCHEMBL7801946 | 0.87 | NR1D1 (0.33) | NR1D1NR1H3 | |
| SCHEMBL17177620 | 0.86 | TSHR (0.32) | NR1D1CA12CA1CA7CA14 | |
| SCHEMBL28323579 | 0.86 | NR1D1 (0.30) | NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341944-B1 | CONJUGATES OF HEXOSE AND METAL COORDINATING COMPOUNDS FOR IMAGING PURPOSES | CURIUM US LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-2341944-B1 | CONJUGATES OF HEXOSE AND METAL COORDINATING COMPOUNDS FOR IMAGING PURPOSES | CURIUM US LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT VETERINARY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT VETERINARY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT VETERINARY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8858916-B2 | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent | MALLINCKRODT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8858916-B2 | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent | MALLINCKRODT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8858916-B2 | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent | MALLINCKRODT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| EP-2341944-A2 | CONJUGATES OF HEXOSE AND METAL COORDINATING COMPOUNDS FOR IMAGING PURPOSES | Mallinckrodt Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010039609-A2 | A VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039609-A2 | A VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-0941120-A4 | BRANCHED PEPTIDE LINKERS | BRISTOL MYERS SQUIBB CO (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-0941120-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998019705-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | NR1D1 1925/4885NR1H3 3709/4885CA12 701/4885 |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | SLC2A1, SLC2A4, SLC2A3 | NR1D1 1925/4885NR1H3 3709/4885CA12 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.